Physician profile
Morgan Bechtle
NPI 1568054237
$2,027.91
in general payments reported to CMS, 2019-2025
21 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $287 · 2022: $435 · 2023: $794 · 2024: $512.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,306.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,306.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $461.43 | 2022-2024 | |
| Novo Nordisk INC | $414.58 | 2021-2024 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $168.34 | 2021-2024 | Otezla, Repatha |
| Lilly USA, LLC | $156.44 | 2021-2024 | Mounjaro, Zepbound, Jardiance |
| Novartis Pharmaceuticals Corporation | $141.82 | 2021-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $117.24 | 2021-2024 | Jardiance |
| Pfizer INC. | $114.53 | 2021-2024 | |
| Glaxosmithkline, LLC. | $83.24 | 2021-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbott Laboratories | $60.00 | 2021-2024 | Freestyle Libre 3 |
| Astrazeneca Pharmaceuticals LP | $57.94 | 2023-2024 | Airsupra, Farxiga |
| Mylan Specialty L.P. | $49.15 | 2022-2023 | Yupelri |
| Merck Sharp & Dohme LLC | $30.51 | 2022 | |
| Astellas Pharma US INC | $28.51 | 2024 | Veozah |
| Biohaven Pharmaceuticals, INC. | $23.67 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $23.63 | 2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $21.26 | 2023 | Quviviq |
| Bayer Healthcare Pharmaceuticals INC. | $16.87 | 2024 | |
| Upsher-Smith Laboratories LLC | $16.71 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $14.30 | 2023 | Ajovy |
| Kowa Pharmaceuticals America, INC. | $14.03 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.71 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Morgan Bechtle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.